Demographic and clinical characteristics recorded after long-term follow-up of previously MVA85A-vaccinated individuals.
- Michele Tameris (23100)
- Hennie Geldenhuys (398842)
- Angelique KanyKany Luabeya (519253)
- Erica Smit (519254)
- Jane E. Hughes (519255)
- Samantha Vermaak (428177)
- Willem A. Hanekom (125097)
- Mark Hatherill (23097)
- Hassan Mahomed (23101)
- Helen McShane (80704)
- Thomas J. Scriba (76847)
Publication date
February 2014
DOIAbstract
@<p>Dose of MVA85A vaccine administered intradermally; pfu, plaque forming units.</p>*<p>We applied TST cut-offs consistent with the original trial protocols, namely 15 mm in TB008, and 10 mm in TB014 and TB011.</p><p>N, participants in the original clinical trial; n, participants re-enrolled.</p
Add to ORKG